Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma - PubMed (original) (raw)

doi: 10.1002/hep.27944. Epub 2015 Aug 7.

Michael B Campion 2, Minetta C Liu 2 3, Roongruedee Chaiteerakij 1 4, Nasra H Giama 1, Hager Ahmed Mohammed 1, Xiaodan Zhang 1, Chunling Hu 1, Victoria L Campion 1, Jin Jen 2, Sudhakar K Venkatesh 5, Kevin C Halling 2, Benjamin R Kipp 2, Lewis R Roberts 1

Affiliations

Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma

Ju Dong Yang et al. Hepatology. 2016 Jan.

Abstract

Circulating tumor cells (CTCs) in blood are associated with poor survival of patients with breast, prostate, or colon cancer. We hypothesized that CTCs are associated with poor survival of patients with cholangiocarcinoma (CCA). Eighty-eight patients with CCA were prospectively enrolled at Mayo Clinic Rochester between June 2010 and September 2014. The CellSearch system by Veridex was used for detection of CTCs in peripheral blood. Associations between CTC, patient and tumor characteristics, and survival were examined using the Cox's proportional hazards model. Fifteen patients (17%) were positive for CTC ≥2 and 8 patients (9%) for CTC ≥5. CTCs were associated with tumor extent. CTC ≥2 (hazard ratio [HR]: 2.5; 95% confidence interval [CI]: 1.1-5.4; P = 0.02) and CTC ≥5 (HR, 4.1; 95% CI: 1.4-10.8; P = 0.01) were both independent predictors of survival. In subgroup analyses, CTC ≥2 (HR, 8.2; 95% CI: 1.8-57.5; P < 0.01) and CTC ≥5 (HR, 7.7; 95% CI: 1.4-42.9; P = 0.02) were both associated with shorter survival among patients with metastasis. There was a trend toward association of CTC ≥5 with shorter survival in patients with nonmetastatic CCA (HR, 4.3; 95% CI: 1.0-13.8; P = 0.06). CTC ≥2 (HR, 10.5; 95% CI: 2.2-40.1; P < 0.01) and CTC ≥5 (HR, 10.2; 95% CI: 1.5-42.3; P = 0.02) were both associated with shorter survival among patients with perihilar/distal CCA. CTC ≥5 was associated with shorter survival of patients with intrahepatic CCA (HR, 4.2; 95% CI: 1.1-14.1; P = 0.04).

Conclusion: CTCs were associated with more-aggressive tumor characteristics and independently associated with survival in patients with CCA. Assessment of CTCs may be useful for identifying CCA patients at risk of early mortality.

© 2015 by the American Association for the Study of Liver Diseases.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest:

Nothing to disclose except that Minetta C. Liu receives research funding from Veridex/Janssen; all funds are provided to the institution with no personal compensation.

Figures

Figure 1

Figure 1

Kaplan-Meier overall survival estimates according to CTC in patients with CCA A: CTC ≥2 vs. CTC <2 B: CTC ≥5 vs. CTC <5

Figure 2

Figure 2

Kaplan-Meier overall survival estimates according to CTC in patients with metastatic/non-metastatic CCA A: CTC ≥2 vs. CTC <2, Metastatic CCA B: CTC ≥5 vs. CTC <5, Metastatic CCA C: CTC ≥2 vs. CTC <2, Non-metastatic CCA D: CTC ≥5 vs. CTC <5, Non-metastatic CCA

Figure 3

Figure 3

Kaplan-Meier overall survival estimates according to CTC in patients with AJCC/UICC TNM stage of 1–2/3–4 CCA A: CTC ≥2 vs. CTC <2, TNM stage of 3–4 CCA B: CTC ≥5 vs. CTC <5, TNM stage of 3–4 CCA C: CTC ≥2 vs. CTC <2, TNM stage of 1–2 CCA D: CTC ≥5 vs. CTC <5, TNM stage of 1–2 CCA

Figure 4

Figure 4

Kaplan-Meier overall survival estimates according to CTC in patients with intrahepatic/perihilar-distal CCA A: CTC ≥2 vs. CTC <2, Intrahepatic CCA B: CTC ≥5 vs. CTC <5, Intrahepatic CCA C: CTC ≥2 vs. CTC <2, Perihilar-distal CCA D: CTC ≥5 vs. CTC <5, Perihilar-distal CCA

Comment in

Similar articles

Cited by

References

    1. Yang JD, Kim B, Sanderson SO, Sauver JS, Yawn BP, Larson JJ, Therneau TM, Roberts LR, Gores GJ, Kim WR. Biliary tract cancers in Olmsted County, Minnesota, 1976–2008. The American journal of gastroenterology. 2012;107:1256–62. - PMC - PubMed
    1. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:14608–13. - PMC - PubMed
    1. Alunni-Fabbroni M, Sandri MT. Circulating tumour cells in clinical practice: Methods of detection and possible characterization. Methods. 2010;50:289–97. - PubMed
    1. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004;10:6897–904. - PubMed
    1. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, Bedrosian I, Kuerer HM, Krishnamurthy S. Circulating tumour cells in non-metastatic breast cancer: a prospective study. The Lancet Oncology. 2012;13:688–95. - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources